The FDA IND clearance for rexaceract is the primary catalyst—Phase 2 initiation in Q3 2026 and final Phase 1b data at MDS Congress in October 2026 are key milestones. Monitor cash runway: $13.1M provides approximately 12-18 months of operations at current burn rate, likely requiring financing before year-end 2027.
Price Chart
Executive Summary
Gain Therapeutics reported Q2 2026 EPS of -$0.11, beating consensus of -$0.15 by 26.7%, with net loss narrowing to $4.7M from $5.8M a year ago. The key catalyst is FDA IND clearance for rexaceract, enabling Phase 2 start in Q3 2026, though cash burn remains high with $13.1M on hand vs $20.8M at year-end 2025.
Key Financial Metrics
Key Facts
- EPS -$0.11 beat consensus -$0.15 by 26.7%
- Net loss narrowed to $4.7M from $5.8M YoY
- FDA IND clearance for rexaceract enables Phase 2 start in Q3 2026
- Cash and equivalents $13.1M as of June 30, 2026, down from $20.8M at Dec 31, 2025
- 14 of 16 Phase 1b extension participants completed Day 270, 7 reached Day 360
- MDS-UPDRS scores show durable non-progression through Day 360
- GT-04686 moving toward IND-enabling studies with target indication by year-end
Financial Impact
EPS beat of $0.04 vs consensus; cash burn $7.8M in H1 2026
Risk Factors
- Cash runway limited to ~12-18 months at current burn rate, likely requiring dilutive financing
- Phase 2 clinical trial may fail to replicate Phase 1b biomarker/clinical signals
- Competition from other GCase-targeting therapies in Parkinson's disease
- Single-asset pipeline risk with rexaceract as only clinical-stage candidate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342533 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | Press Release | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.15 (−33.14%) |
Oct 1, 2026 25d ago | 8-K | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.15 (−33.14%) |
Aug 11, 2026 11w ago | Press Release | $2.06 $2.03 | ▼ −1.46% | ▼ −1.05% | $1.15 (−44.17%) |
Jul 16, 2026 14w ago | 8-K | $1.66 $1.82 | ▲ +9.64% | ▲ +11.31% | $1.15 (−30.72%) |
Jun 29, 2026 17w ago | 8-K | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.15 (−43.35%) |
Jun 29, 2026 17w ago | Press Release | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.15 (−43.35%) |
May 26, 2026 21w ago | 8-K | $1.82 $1.96 | ▲ +7.69% | ▲ +6.61% | $1.15 (−36.81%) |
May 11, 2026 24w ago | Press Release | $1.82 $1.62 | ▼ −10.99% | ▼ −10.90% | $1.15 (−36.81%) |
Apr 28, 2026 25w ago | DEFA14A | $1.76 $1.91 | ▲ +8.52% | ▲ +5.41% | $1.15 (−34.66%) |
Mar 26, 2026 30w ago | Press Release | $1.89 $1.85 | ▼ −2.12% | ▼ −3.75% | $1.15 (−39.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers